Deoxypodophyllotoxin Induces a Th1 Response and Enhances the Antitumor Efficacy of a Dendritic Cell-based Vaccine
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Dendritic cell (DC)-based vaccines are currently being evaluated as a novel strategy for tumor vaccination and immunotherapy. However, inducing long-term regression in established tumor-implanted mice is difficult. Here, we show that deoxypohophyllotoxin (DPT) induces maturation and activation of bone marrow-derived DCs via Toll-like receptor (TLR) 4 activation of MAPK and NF-κB. Methods: The phenotypic and functional maturation of DPT-treated DCs was assessed by flow cytometric analysis and cytokine production, respectively. DPT-treated DCs was also used for mixed leukocyte reaction to evaluate T cell-priming capacity and for tumor regression against melanoma. Results: DPT promoted the activation of CD8＋ T cells and the Th1 immune response by inducing IL-12 production in DCs. In a B16F10 melanoma-implanted mouse model, we demonstrated that DPT-treated DCs (DPT-DCs) enhance immune priming and regression of an established tumor in vivo. Furthermore, migration of DPT-DCs to the draining lymph nodes was induced via CCR7 upregulation. Mice that received DPT-DCs displayed enhanced antitumor therapeutic efficacy, which was associated with increased IFN-γproduction and induction of cytotoxic T lymphocyte activity. Conclusion: These findings strongly suggest that the adjuvant effect of DPT in DC vaccination is associated with the polarization of T effector cells toward a Th1 phenotype and provides a potential therapeutic antitumor immunity.
Abstract
Background: Dendritic cell (DC)-based vaccines are currently being evaluated as a novel strategy for tumor vaccination and immunotherapy. However, inducing long-term regression in established tumor-implanted mice is difficult. Here, we show that deoxypohophyllotoxin (DPT) induces maturation and activation of bone marrow-derived DCs via Toll-like receptor (TLR) 4 activation of MAPK and NF-κB. Methods: The phenotypic and functional maturation of DPT-treated DCs was assessed by flow cytometric analysis and cytokine production, respectively. DPT-treated DCs was also used for mixed leukocyte reaction to evaluate T cell-priming capacity and for tumor regression against melanoma. Results: DPT promoted the activation of CD8＋ T cells and the Th1 immune response by inducing IL-12 production in DCs. In a B16F10 melanoma-implanted mouse model, we demonstrated that DPT-treated DCs (DPT-DCs) enhance immune priming and regression of an established tumor in vivo. Furthermore, migration of DPT-DCs to the draining lymph nodes was induced via CCR7 upregulation. Mice that received DPT-DCs displayed enhanced antitumor therapeutic efficacy, which was associated with increased IFN-γproduction and induction of cytotoxic T lymphocyte activity. Conclusion: These findings strongly suggest that the adjuvant effect of DPT in DC vaccination is associated with the polarization of T effector cells toward a Th1 phenotype and provides a potential therapeutic antitumor immunity.
참고문헌 (50)
- Tobiásová Z, "In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients", Clin Immunol, 122, pp.18~27 (2007)
- Bennett SR, "Induction of a CD8＋ cytotoxic T lymphocyte response by cross-priming requires cognate CD4＋ T cell help", J Exp Med, 186, pp.65~70 (1997)
- Steinman RM, "The dendritic cell system and its role in immunogenicity", Annu Rev Immunol, 9, pp.271~296 (1991)
- Morisaki T, "Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives", Hum Cell, 16, pp.175~182 (2003)
- Rock KL, "Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway", J Immunol, 156, pp.3721~3726 (1996)
- Salio M, "Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells", Eur J Immunol, 30, pp.705~708 (2000)
- Shimizu K, "Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein", Cancer Res, 61, pp.2618~2624 (2001)
- Jeannin P, "OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway", Nat Immunol, 1, pp.502~509 (2000)
- Sloan JM, "MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells", Cancer Gene Ther, 9, pp.946~950 (2002)
- Albert ML, "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs", Nature, 392, pp.86~89 (1998)
- You Z, "A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses", Cancer Res, 61, pp.197~205 (2001)
- Celluzzi CM, "Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity", J Exp Med, 183, pp.283~287 (1996)
- Huang J, "Nitric oxide sensitizes tumor cells to dendritic cellmediated apoptosis, uptake, and cross-presentation", Cancer Res, 65, pp.8461~8470 (2005)
- Liu Y, "Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses", Cancer Res, 65, pp.4955~4962 (2005)
- Jarnicki AG, "Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics", J Immunol, 180, pp.3797~3806 (2008)
- Zanoni I, "TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells", J Immunol, 175, pp.286~292 (2005)
- Kane CM, "Helminth antigens modulate TLR-initiated dendritic cell activation", J Immunol, 173, pp.7475~7461 (2004)
- Krieg AM, "Therapeutic potential of Toll-like receptor 9 activation", Nat Rev Drug Discov, 5, pp.471~484 (2006)
- Chan CW, "Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity", Nat Med, 12, pp.207~213 (2006)
- Kapsenberg ML, "Dendritic-cell control of pathogen-driven T-cell polarization", Nat Rev Immunol, 3, pp.984~993 (2003)
- Lee JS, "Outer membrane protein A of Acinetobacter baumannii induces differentiation of CD4(+) T cells toward a Th1 polarizing phenotype through the activation of dendritic cells", BIOCHEMICAL PHARMACOLOGY, 74, pp.86~97 (2007), PERGAMON-ELSEVIER SCIENCE LTD
- Sivori S, "CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells", Proc Natl Acad Sci U S A, 101, pp.10116~10121 (2004)
- Kim Y, "Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana", Planta Med, 68, pp.271~274 (2002)
- Sudo K, "Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication", Antivir Chem Chemother, 9, pp.263~267 (1998)
- Jin M, "The naturally occurring flavolignan, deoxypodophyllotoxin, inhibits lipopolysaccharide-induced iNOS expression through the NK-kB activation in RAW264.7 macrophage cells", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, 31(7), pp.1312~1315 (2008), PHARMACEUTICAL SOC JAPAN
- Lyons AB, "Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution", J Immunol Methods, 243, pp.147~154 (2000)
- Préville X, "Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein", Cancer Res, 65, pp.641~649 (2005)
- Abe M, "Migratory responses of murine hepatic myeloid, lymphoid-related, and plasmacytoid dendritic cells to CC chemokines", Transplantation, 78, pp.762~765 (2004)
- Mosca PJ, "A subset of human monocyte- derived dendritic cells expresses high levels of interleukin- 12 in response to combined CD40 ligand and interferon- gamma treatment", Blood, 96, pp.3499~3504 (2000)
- Langenkamp A, "Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells", Nat Immunol, 1, pp.311~316 (2000)
- Trinchieri G, "Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity", Annu Rev Immunol, 13, pp.251~276 (1995)
- Lutz MB, "Different cytokines regulate antigen uptake and presentation of a precursor dendritic cell line", Eur J Immunol, 26, pp.586~594 (1996)
- An H, "Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells", Immunology, 106, pp.38~45 (2002)
- MacDonald KP, "Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD", Blood, 109, pp.5049~5057 (2007)
- Sioud M, "TLR agonists induce the differentiation of human bone marrow CD34＋ progenitors into CD11c＋ CD80", 86＋ DC capable of inducing a Th1-type response, 2007, pp.37, 2834~2846
- Sweet CR, "YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction", Cell Microbiol, 9, pp.2700~2715 (2007)
- Guiducci C, "PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation", J Exp Med, 205, pp.315~322 (2008)
- Ato M, "Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis", Nat Immunol, 3, pp.1185~1191 (2002)
- Catusse J, "Immunomodulation by herpesvirus U51A chemokine receptor via CCL5 and FOG-2 down-regulation plus XCR1 and CCR7 mimicry in human leukocytes", Eur J Immunol, 38, pp.763~777 (2008)
- Movassagh M, "Selective accumulation of mature DC-Lamp＋ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma", Cancer Res, 64, pp.2192~2198 (2004)
- Sancho D, "Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin", J Clin Invest, 118, pp.2098~2110 (2008)
- Melief CJ, "Cancer immunotherapy by dendritic cells", Immunity, 29, pp.372~383 (2008)
- Hatfield P, "Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy", J Immunother, 31, pp.620~632 (2008)
- Okada N, "Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells", Cancer Res, 61, pp.7913~7919 (2001)
- Jun Sik Lee, "Anti-Tumor Activity of Acinetobacter baumannii Outer Membrane Protein A on Dendritic Cell-Based Immunotherapy against Murine Melanoma", The Journal of Microbiology, 46(2), pp.221~227 (2008), 한국미생물학회
- Usluoglu N, "RIP2 mediates LPS-induced p38 and IkappaBalpha signaling including IL-12 p40 expression in human monocyte-derived dendritic cells", Eur J Immunol, 37, pp.2317~2325 (2007)
- Kelsall BL, "Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses", Ann N Y Acad Sci, 795, pp.116~126 (1996)
- Iwashita Y, "Dendritic cell immunotherapy with poly (D,L-2,4-diaminobutyric acid)-mediated intratumoral delivery of the interleukin-12 gene suppresses tumor growth significantly", Cancer Sci, 96, pp.303~307 (2005)
- Takaoka A, "Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors", Nature, 434, pp.243~249 (2005)
- Ridge JP, "A conditioned dendritic cell can be a temporal bridge between a CD4＋ T-helper and a T-killer cell", Nature, 393, pp.474~478 (1998)